loader2
Partner With Us NRI

Themis Medicare Ltd

Company details

1,197.95
1,298.90
692.00
1,434.25
6M Return 54.16%
1Y Return 20.44%
Mkt Cap.(Cr) 1,126.08
Volume 1,242
Div Yield 0.39%
OI
-
OI Chg %
-
Volume 1,242

Open Free Demat Account Online with ICICIDIRECT

FINANCIALS

Sales

Operating Profit

Profit after Tax

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after Tax

PE

Debt/Equity

P BV

COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 287.49 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 17,871.26 -28,732.63
LAST 3M 35,065.84 -30,146.79
LAST 6M 57,360.50 38,576.46
LAST 12M 186,944.70 -113,961.48

Board Meeting for Today

Feb 03, 2023 l Board Meetings for Today

Themis Medicare Limited - Outcome of Board Meeting

Feb 03, 2023 l NSE Announcement

NSE Board Meetings Forthcomming

Feb 03, 2023 l NSE Board Meetings Forthcomming

Date Action Type Ratio
Sep 08, 2022 Dividend 50
Sep 08, 2021 Dividend 43

INFORMATION

Stock PE (TTM)

20.06

Promoter Holding

67.18%

Book Value

308.3028

ROCE

34.44%

ROE

33.33%

Description

  • Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. In Mar.`95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital. Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments. Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary. The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.

No Data Found

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 530199
NSE Code : THEMISMED
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE083B01016

ICICIdirect Themis Medicare Ltd FAQ

You can buy Themis Medicare Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Themis Medicare Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Feb 03, 2023 04:01 PM the closing price of Themis Medicare Ltd was ₹ 1,224.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Feb 03, 2023 04:01 PM, the market cap of Themis Medicare Ltd stood at ₹ 1,126.08.
The latest PE ratio of Themis Medicare Ltd as of Feb 03, 2023 04:01 PM is 20.06
The latest PB ratio of Themis Medicare Ltd as of Feb 03, 2023 04:01 PM is 0.24
The 52-week high of Themis Medicare Ltd is ₹ 1,434.25 while the 52-week low is ₹ 692.00

Download Our App

market app
market app